文献速递淋巴瘤

CD5作为B细胞受体信号负调控因子在慢性淋巴细胞白血病中的表达与临床结局

Clinical outcomes in chronic lymphocytic leukaemia associated with expression of CD5, a negative regulator of B-cell receptor signalling.
PubMed 文献 · Br J Haematol · 2018-11-08

研究评估1275份血样中CD5表达与423例慢性淋巴细胞白血病(CLL)患者临床结局的关系。CD5中位荧光强度(MFI)在个体患者中基本稳定,全队列范围0.5至760。较低CD5 MFI与较短至首次治疗时间显著相关,CD5 MFI联合已有临床和分子预后标志物可显著改善风险分层。

要点

  • CD5中位荧光强度(MFI)在个体患者中基本稳定,全队列范围0.5至760。
  • 较低CD5 MFI与较短至首次治疗时间显著相关。
  • CD5 MFI联合已有临床和分子预后标志物可显著改善风险分层。

核心结论

  • CD5可能通过抑制B细胞受体(BCR)信号传导影响疾病结局。
  • 调节CLL细胞CD5表达或功能的策略可能成为CLL的治疗方法。

研究设计与样本

  • 研究纳入在杜克大学和达勒姆VA医疗中心随访的423例CLL患者,评估1275份血样的CD5表达、已建立的预后标志物及至事件时间数据。

主要发现

  • CD5中位荧光强度(MFI)在个体患者中基本稳定,但全队列范围在0.5至760之间。
  • 较低CD5 MFI与较短至首次治疗时间显著相关。
  • CD5 MFI联合已建立的临床和分子预后标志物可显著改善风险分层。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Chronic lymphocytic leukaemia (CLL) is characterized by expression of CD5 on clonal B cells, and is partly driven by activated B-cell receptor (BCR) signalling. While CD5 is known to be a negative regulator of BCR signalling, it is unknown if variability in CD5 expression exists among patients and whether CLL cell CD5 expression affects CLL clinical outcomes. We assessed the extent to which CD5 expression is correlated with clinical outcomes, and whether this information adds to currently used prognostic markers. We evaluated CD5 expression from 1275 blood samples, established prognostic markers and time to event data from 423 CLL patients followed at the Duke University and Durham VA Medical Centers. CD5 median fluorescence intensity (MFI) was largely stable over time in individual patients, but ranged between 0·5 and 760 in the entire cohort. Lower CD5 MFI was significantly associated with a shorter time to first therapy. CD5 MFI, combined with established clinical and molecular prognostic markers, significantly improved risk-stratification. CD5 may affect disease outcomes by suppressing signalling through the BCR. Thus, a strategy to modulate CLL cell CD5 expression or function could be a therapeutic approach in CLL.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Friedman DR, Guadalupe E, Volkheimer A, et al. Clinical outcomes in chronic lymphocytic leukaemia associated with expression of CD5, a negative regulator of B-cell receptor signalling. Br J Haematol. 2018. PMID: 30407619. doi:10.1111/bjh.15632

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。